Lowell J A, Brennan D C, Shenoy S, Hagerty D, Miller S, Ceriotti C, Cole B, Howard T K
Departments of Surgery, Medicine, and Pediatrics, Washington University School of Medicine, St. Louis, Mo., USA.
Surgery. 1996 May;119(5):538-43. doi: 10.1016/s0039-6060(96)80264-9.
The increasing success of renal transplantation is paralleled by the increased size of the waiting list. Efforts to increase the donor pool have included the use of living-unrelated kidney donors (LURDs).
During a 12-year period our center performed 309 transplantation from living donors; 279 patients received living-related donor (LRD) transplants, and 30 patients received LURD transplants. During the same period 543 patients received cadaveric renal donor transplants. A total of 86.7% of LURD transplants were spousal transplants. A total of 29% of the patients who received LRDs were human leukocyte antigen-identical with their donors and 53% were haploidentical, versus 0 human leukocyte antigen-identical or haploidentical in the LURD group.
Twenty-seven (90%) Of 30 LURD recipients are alive, as are 240 (86%) of 279 LRD recipients. Mean current creatinine is 1.6 mg/dl for the LURD group and 1.7 mg/dl for the LRD group Kaplan-Meier 1- and 5-year graft survival was 94.9% and 82.9% for the LRD group, 93.1% and 85.9% for the LURD group (p = not significant), and 84.6% and 70.7% for the cadaveric renal donor group (p < 0.05).
LURD patient and graft survival is comparable to LRD transplants despite inferior human leukocyte antigen matching. LURD transplant survival is superior to that of cadaveric renal donor transplants. LURDs are an excellent but underused source of organs for renal transplant recipients.
肾移植成功率的提高伴随着等待名单规模的扩大。增加供体库的努力包括使用非亲属活体肾供体(LURD)。
在12年期间,我们中心进行了309例活体供体移植;279例患者接受了亲属活体供体(LRD)移植,30例患者接受了LURD移植。同期,543例患者接受了尸体肾供体移植。LURD移植中共有86.7%为配偶间移植。接受LRD移植的患者中,共有29%与供体人类白细胞抗原完全相同,53%为单倍型相同,而LURD组中这两个比例均为0。
30例LURD受者中有27例(90%)存活,279例LRD受者中有240例(86%)存活。LURD组目前的平均肌酐水平为1.6mg/dl,LRD组为1.7mg/dl。LRD组的Kaplan-Meier 1年和5年移植物存活率分别为94.9%和82.9%,LURD组为93.1%和85.9%(p值无统计学意义),尸体肾供体组为84.6%和70.7%(p<0.05)。
尽管人类白细胞抗原匹配较差,但LURD患者和移植物的存活率与LRD移植相当。LURD移植的存活率高于尸体肾供体移植。LURD是肾移植受者极好但未得到充分利用的器官来源。